These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 12057547)

  • 1. Use of recombinant thyrotropin.
    Toft A; Beckett G
    Lancet; 2002 Jun; 359(9321):1874-5. PubMed ID: 12057547
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
    Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirically treating high serum thyroglobulin levels.
    Mazzaferri EL
    J Nucl Med; 2005 Jul; 46(7):1079-88. PubMed ID: 16000275
    [No Abstract]   [Full Text] [Related]  

  • 4. [Taking of position in relationship to the protocol of the current treatment of thyroid nodules and differentiated thyroid cancer].
    Gómez Sáez JM
    Endocrinol Nutr; 2010 Oct; 57(8):370-5. PubMed ID: 20850397
    [No Abstract]   [Full Text] [Related]  

  • 5. Conservative management of thyroglobulin-positive, nonlocalizable thyroid carcinoma.
    Frank RW; Middleton L; Stack BC; Spencer HJ; Riggs AT; Bodenner DL
    Head Neck; 2014 Feb; 36(2):155-7. PubMed ID: 23728951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid cancer without diagnostic (131)I scanning.
    Wartofsky L
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1486-9. PubMed ID: 11932269
    [No Abstract]   [Full Text] [Related]  

  • 9. Thyroglobulin before ablative radioiodine therapy.
    Grünwald F; Menzel C; Biersack HJ
    Eur J Nucl Med; 2000 Apr; 27(4):461. PubMed ID: 10805121
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin. Diagnostic implication of TSH-stimulated antithyroglobulin antibody.
    Nam HY; Paeng JC; Chung JK; Kang KW; Cheon GJ; Kim Y; Park DJ; Park YJ; Min HS; Lee DS
    Nuklearmedizin; 2014; 53(2):32-8. PubMed ID: 24276613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of thyroid cancer.
    Blahd WH
    Compr Ther; 1993; 19(5):197-202. PubMed ID: 8275665
    [No Abstract]   [Full Text] [Related]  

  • 12. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
    Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
    Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing concepts in the management of differentiated thyroid cancer.
    Intenzo CM; Jabbour S; Dam HQ; Capuzzi DM
    Semin Nucl Med; 2005 Oct; 35(4):257-65. PubMed ID: 16150246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
    Lee JI; Chung YJ; Cho BY; Chong S; Seok JW; Park SJ
    Surgery; 2013 Jun; 153(6):828-35. PubMed ID: 23489940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment and follow-up of thyroid cancer].
    Välimäki M
    Duodecim; 1991; 107(6):456-60. PubMed ID: 1364893
    [No Abstract]   [Full Text] [Related]  

  • 16. [Guidelines for the management of differentiated thyroid cancers].
    Ann Endocrinol (Paris); 2007 Dec; 68 Suppl 2():S57-72. PubMed ID: 18342281
    [No Abstract]   [Full Text] [Related]  

  • 17. [After care of differentiated thyroid gland carcinoma with special reference to serum thyroglobulin level].
    Kanitz W; Böttger IG; Pabst HW; Heidenreich P; Dirr W
    Rofo; 1987 Sep; 147(3):282-7. PubMed ID: 2823333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radioiodine therapy for thyroid cancer].
    Misaki T
    Nihon Rinsho; 2007 Nov; 65(11):2049-52. PubMed ID: 18018569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thyroid cancers. Pathology, diagnosis].
    Wemeau JL
    Rev Prat; 2001 Jan; 51(2):187-91. PubMed ID: 11252946
    [No Abstract]   [Full Text] [Related]  

  • 20. Thyroid peroxidase (TPO) as a tumor marker in the follow-up of differentiated thyroid carcinomas with surgical and ablative radioiodine therapy. An assessment after evaluation.
    Franke WG; Zöphel K; Wunderlich G; Kühne A; Schimming C; Kropp J; Bredow J
    Anticancer Res; 1999; 19(4A):2711-6. PubMed ID: 10470226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.